Pacira BioSciences' Share-based Compensation rose 565.38% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 963.27%. This contributed to the annual value of $51.2 million for FY2024, which is 684.0% up from last year.
According to the latest figures from Q3 2025, Pacira BioSciences' Share-based Compensation is $14.0 million, which was up 565.38% from $15.5 million recorded in Q2 2025.
Over the past 5 years, Pacira BioSciences' Share-based Compensation peaked at $15.5 million during Q2 2025, and registered a low of $10.1 million during Q1 2021.
Its 5-year average for Share-based Compensation is $12.3 million, with a median of $12.4 million in 2023.
In the last 5 years, Pacira BioSciences' Share-based Compensation plummeted by 510.22% in 2023 and then surged by 2353.88% in 2025.
Pacira BioSciences' Share-based Compensation (Quarter) stood at $10.9 million in 2021, then increased by 16.41% to $12.7 million in 2022, then dropped by 2.03% to $12.4 million in 2023, then dropped by 1.24% to $12.3 million in 2024, then rose by 13.96% to $14.0 million in 2025.
Its last three reported values are $14.0 million in Q3 2025, $15.5 million for Q2 2025, and $14.6 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value